OBJECTIVE:
Amniochorion is a source of interleukin-8 during
infection and inflammation. In this study we investigate the role of 2
immunoinhibitory cytokines, transforming growth factor and interleukin- 10,
in regulating interleukin-8 production from human fetal membranes and
define their mechanism of regulation.
STUDY DESIGN:
Amniochorion was
placed in an organ explant system for 72 hours. Tissues were
stimulated with lipopolysaccharide (50 ng/mL), lipopolysaccharide
transforming growth factor-beta (50/50, 50/100), transforming growth
factor-beta (50 and 100 ng/mL), lipopolysaccharide interleukin-10
(50/50 and 50/100), and interleukin-10 (50 and 100 ng/mL) in culture.
Tissue and media samples were frozen until quantitation of
interleukin- 8 messenger ribonucleic acid and protein. Quantitation
of messenger ribonucleic acid was performed by quantitative
competitive polymerase chain reaction and protein by enzyme-linked
immunoassay, respectively.
RESULTS:
Lipopolysaccharide-stimulated
tissues produced approximately 6 x 10(6) molecules per microliter of
interleukin-8 messenger ribonucleic acid compared with 6 x 10(3)
molecules per microliter in controls. Transforming growth factor-beta
and lipopolysaccharide plus transforming growth factor-beta
stimulation produced 6 x 10(5) and 6 x 10(4) molecules of
interleukin-8 messenger ribonucleic acid per microliter, respectively.
Tissues stimulated with lipopolysaccharide plus 50 ng/mL interleukin-10 produced approximately 600 molecules per
microliter of interleukin-8 messenger ribonucleic acid, whereas no
amplifiable messenger ribonucleic acid was detected in tissues
treated with lipopolysaccharide plus 100 ng/mL interleukin-10.
Tissues treated with interleukin-10 alone produced 6 x 10(3)
molecules of messenger ribonucleic acid, similar to control levels.
Enzyme-linked immunosorbent assay data showed similar levels of
interleukin-8 peptide release from lipopolysaccharide and
lipopolysaccharide plus transforming growth factor-beta-treated
fetal membranes. A dose- dependent decrease in interleukin-8
peptide release was seen in tissues treated with lipopolysaccharide
plus interleukin-10, whereas stimulation with transforming growth
factor or interleukin-10 alone resulted in interleukin-8 peptide
release similar to that of control levels.
CONCLUSIONS:
Transforming growth
factor-beta seems to have no effect on interleukin-8 protein
production in the presence of an infectious agent; however,
a drop in messenger ribonucleic acid levels was observed.
Interleukin-10 in the presence of lipopolysaccharide showed
down-regulation of interleukin-8 messenger ribonucleic acid
expression and peptide production. These data suggest that fetal
membrane interleukin-8 production can be controlled by interleukin-10
during an infectious process.